PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?

Yao, 2008, One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol : official journal of the American Society of Clinical Oncology, 26, 3063, 10.1200/JCO.2007.15.4377 Leoncini, 2017, Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms, Endocrine, 58, 368, 10.1007/s12020-017-1273-x Jann, 2011, Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome, Cancer, 117, 3332, 10.1002/cncr.25855 Panzuto, 2011, Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression, J Clin Oncol : official journal of the American Society of Clinical Oncology, 29, 2372, 10.1200/JCO.2010.33.0688 Perren, 2017, ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification, Neuroendocrinology, 105, 196, 10.1159/000457956 Nagtegaal, 2020, The 2019 WHO classification of tumours of the digestive system, Histopathology, 76, 182, 10.1111/his.13975 Frilling, 2014, Recommendations for management of patients with neuroendocrine liver metastases, Lancet Oncol, 15, e8, 10.1016/S1470-2045(13)70362-0 Sorbye, 2020, PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3), Endocr Relat Cancer, 27, R67, 10.1530/ERC-19-0400 Hicks, 2017, ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues, Neuroendocrinology, 105, 295, 10.1159/000475526 Strosberg, 2017, Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors, N Engl J Med, 376, 125, 10.1056/NEJMoa1607427 Strosberg, 2018, Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-dotatate in the phase III NETTER-1 trial, J Clin Oncol : official journal of the American Society of Clinical Oncology, 36, 2578, 10.1200/JCO.2018.78.5865 Strosberg, 2021, Lu-Dotatate plus long-acting octreotide versus highdose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial, Lancet Oncol, 22, 1752, 10.1016/S1470-2045(21)00572-6 2021 Hope, 2020, NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-dotatate peptide receptor radionuclide therapy, J Nucl Med, 61, 222, 10.2967/jnumed.119.240911 Pavel, 2020, Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol : official journal of the European Society for Medical Oncology/ESMO, 31, 844, 10.1016/j.annonc.2020.03.304 Pavel, 2016, ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site, Neuroendocrinology, 103, 172, 10.1159/000443167 Velayoudom-Cephise, 2013, Are G3 ENETS neuroendocrine neoplasms heterogeneous?, Endocr Relat Cancer, 20, 649, 10.1530/ERC-13-0027 Milione, 2017, The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories, Neuroendocrinology, 104, 85, 10.1159/000445165 Tang, 2016, A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas, Am J Surg Pathol, 40, 1192, 10.1097/PAS.0000000000000662 Heetfeld, 2015, Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms, Endocr Relat Cancer, 22, 657, 10.1530/ERC-15-0119 Fazio, 2016, Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: new insights and treatment implications, Cancer Treat Rev, 50, 61, 10.1016/j.ctrv.2016.08.006 Sorbye, 2013, Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study, Ann Oncol : official journal of the European Society for Medical Oncology/ESMO, 24, 152, 10.1093/annonc/mds276 Thang, 2018, Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis, Eur J Nucl Med Mol Imag, 45, 262, 10.1007/s00259-017-3821-2 Nicolini, 2018, Investigation of receptor radionuclide therapy with (177)Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index, Eur J Nucl Med Mol Imag, 45, 923, 10.1007/s00259-017-3925-8 Carlsen, 2019, Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study, Endocr Relat Cancer, 26, 227, 10.1530/ERC-18-0424 Zhang, 2019, Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients, J Nucl Med, 60, 377, 10.2967/jnumed.118.215848 Waseem, 2019, Evaluating the role of theranostics in grade 3 neuroendocrine neoplasms, J Nucl Med, 60, 882, 10.2967/jnumed.118.217851 Kong, 2019, Peptide receptor radiotherapy: current approaches and future directions, Curr Treat Options Oncol, 20, 77, 10.1007/s11864-019-0677-7 Ezziddin, 2006, Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors, J Nucl Med, 47, 223 Kayani, 2008, Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG, Cancer, 112, 2447, 10.1002/cncr.23469 Garin, 2009, Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors, J Nucl Med, 50, 858, 10.2967/jnumed.108.057505 Zhang, 2018, vol. 2018 Sorbye, 2018, The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond, Endocrinol Metab Clin N Am, 47, 683, 10.1016/j.ecl.2018.05.001 Walter, 2017, Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort, Eur J Cancer, 79, 158, 10.1016/j.ejca.2017.04.009 Tang, 2016, Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas, Clin Cancer Res : an official journal of the American Association for Cancer Research, 22, 1011, 10.1158/1078-0432.CCR-15-0548 Shi, 2015, Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors, Am J Clin Pathol, 143, 398, 10.1309/AJCPQ55SKOCYFZHN Chan, 2017, Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance, Theranostics, 7, 1149, 10.7150/thno.18068 Carideo, 2019, Role of combined [(68)Ga]Ga-DOTA-SST analogues and [(18)F]FDG PET/CT in the management of GEP-NENs: a systematic review, J Clin Med, 8 Kashyap, 2015, Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours, Eur J Nucl Med Mol Imag, 42, 176, 10.1007/s00259-014-2906-4 Ambrosini, 2021, Consensus on molecular imaging and theranostics in neuroendocrine neoplasms, Eur J Cancer, 146, 56, 10.1016/j.ejca.2021.01.008 Violet, 2019, Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes, J Nucl Med, 60, 517, 10.2967/jnumed.118.219352 Beauregard, 2012, The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy, Eur J Nucl Med Mol Imag, 39, 50, 10.1007/s00259-011-1937-3 Pandit-Taskar, 2021, Dosimetry in clinical radiopharmaceutical therapy of cancer: practicality versus perfection in current practice, J Nucl Med, 62, 60S, 10.2967/jnumed.121.262977 Lawhn-Heath, 2022, Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose, Lancet Oncol, 23, e75, 10.1016/S1470-2045(21)00657-4 Sjogreen Gleisner, 2022, EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands, Eur J Nucl Med Mol Imag, 49, 1778, 10.1007/s00259-022-05727-7 Hicks, 2019, First-in-human trial of (64)Cu-SARTATE PET imaging of patients with neuroendocrine tumours demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy, J Nucl Med, 60, 777, 10.2967/jnumed.118.217745 Wild, 2014, Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study, J Nucl Med, 55, 1248, 10.2967/jnumed.114.138834 Nicolas Ca, 2020, An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): an interim analysis, Ann Oncol, 31, S711 de Jong, 2005, Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs, J Nucl Med, 46 Villard, 2012, Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers, J Clin Oncol : official journal of the American Society of Clinical Oncology, 30, 1100, 10.1200/JCO.2011.37.2151 Dumont, 2015, Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma, Am J Nucl Med Mol Imaging, 5, 46 Kong, 2017, High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours, Eur J Nucl Med Mol Imag, 44, 476, 10.1007/s00259-016-3527-x Navalkissoor, 2019, Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy, Neuroendocrinology, 108, 256, 10.1159/000494760 Kratochwil, 2014, (2)(1)(3)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience, Eur J Nucl Med Mol Imag, 41, 2106, 10.1007/s00259-014-2857-9 Nayak, 2007, Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells, Nucl Med Biol, 34, 185, 10.1016/j.nucmedbio.2006.11.006 Ballal, 2020, Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety, Eur J Nucl Med Mol Imag, 47, 934, 10.1007/s00259-019-04567-2 Yadav, 2022, Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study, Eur J Nucl Med Mol Imag, 49, 1595, 10.1007/s00259-021-05632-5 Delpassand, 2022, Targeted alpha-emitter therapy with (212)Pb-dotamtate for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial, J Nucl Med, 63, 1326, 10.2967/jnumed.121.263230 van Essen, 2008, Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours, Eur J Nucl Med Mol Imag, 35, 743, 10.1007/s00259-007-0688-7 Claringbold, 2011, Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours, Eur J Nucl Med Mol Imag, 38, 302, 10.1007/s00259-010-1631-x Hubble, 2010, 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide, Eur J Nucl Med Mol Imag, 37, 1869, 10.1007/s00259-010-1483-4 Kong, 2009, High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience, Cancer Biother Rad, 24, 527 Kong, 2014, Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT), Eur J Nucl Med Mol Imag, 41, 1831, 10.1007/s00259-014-2788-5 Claringbold, 2016, Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-Octreotate-Capecitabine-Temozolomide radiopeptide chemotherapy, Neuroendocrinology, 103, 432, 10.1159/000434723 Kennedy, 2022, Long-term survival and toxicity in patients with neuroendocrine tumors treated with (177) Lu-octreotate peptide radionuclide therapy, Cancer, 128, 2182, 10.1002/cncr.34191 Parghane, 2021, Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease, Eur J Nucl Med Mol Imag, 48, 913, 10.1007/s00259-020-05004-5 Nonnekens, 2016, Potentiation of peptide receptor radionuclide therapy by the PARP inhibitor olaparib, Theranostics, 6, 1821, 10.7150/thno.15311 Cullinane, 2020, Enhancing the anti-tumour activity of (177)Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP, Sci Rep, 10, 10.1038/s41598-020-67199-9 Kim, 2020, Phase I study of the 177Lu-DOTA 0- Tyr 3- Octreotate (Lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung, J Immunother Cancer, 8